Treatment of behavioral emergencies: A summary of the expert consensus guidelines

Journal of Psychiatric Practice

Volumn 9, Issue 1, 2003, Pages 16-38

  Allen, Michael H ^a   Currier, Glenn W ^b   Hughes, Douglas H ^b   Docherty, John P ^b   Carpenter, Daniel ^b   Ross, Ruth ^b  

^a UNIVERSITY OF COLORADO HOSPITAL   (United States)

^b NONE

Author keywords

Culture change; Individualized treatment; Restraint; Seclusion; Training

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; DROPERIDOL; NEUROLEPTIC AGENT;

BEHAVIORAL MEDICINE; DEPRESSIVE PSYCHOSIS; DOCTOR PATIENT RELATION; DRUG USE; EMERGENCY TREATMENT; HUMAN; MANIA; MEDICAL DECISION MAKING; MENTAL HEALTH CARE; NURSING; PRACTICE GUIDELINE; REVIEW; SCHIZOPHRENIA;

EID: 0037499575     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/00131746-200301000-00004     Document Type: Review

References (82)

1. Allen MH. Building level I psychiatric emergency services: Tools of the crisis sector. Psychiatr Clin North Am 1999; 22:713-34.
2. Fisher WA. Restraint and seclusion: A review of the literature. Am J Psychiatry 1994;151:1584-91.
3. Laughren T. Regulatory issues on behavioral and psychological symptoms of dementia in the United States. International Psychogeriatrics 2000;12(suppl 1):331-6.
4. Snyder W. Hospital downsizing and increased frequency of assaults on staff. Hosp Community Psychiatry 1994;45:378-80.
5. Currier GW, Allen MH. Emergency psychiatry: Physical and chemical restraint in the psychiatric emergency service. Psychiatr Serv 2000;51:717-9.
6. Meyerson AT, Delaney B, Herbert JD, et al. Do aspects of standard emergency care have potentially traumatic sequelae? Emergency Psychiatry 1998;45:44-8.
7. Binder RL, McCoy SM. A study of patients' attitudes toward placement in seclusion. Hosp Community Psychiatry 1983;34:1052-4.
8. Sundram CJ, Stack EW, Benjamin WP. Restraint and seclusion practices in New York State psychiatric facilities. Albany, NY: New York State Commission on Quality of Care for the Mentally Disabled, 1994.
9. Way BB, Banks SM. Use of seclusion and restraint in public psychiatric hospitals: Patient characteristics and facility effects. Hosp Community Psychiatry 1990;41:75-81.
10. Allen MH, Currier GW. Use of restraints and pharmacotherapy in psychiatric emergency services. Gen Hosp Psychiatry (submitted).
11. Altimari D, Blint DF, Weiss EM, et al. Deadly restraint. Hartford: Hartford Courant; 1998. (Summary available at http://www.nami.org/update/990324.html).
12. Medical Directors Council of the National Association of State Mental Health Program Directors. Reducing the use of seclusion and restraint: Findings, strategies, and recommendations. Alexandria, VA: National Association of State Mental Health Program Directors, 1999.
13. National Alliance for the Mentally Ill. Cries of anguish: A summary of reports of restraints and seclusions abuse received since the October 1998 investigation by The Hartford Courant. (Available at http://www.nami.org/update/hartford.html).
14. U.S. Department of Health and Human Services, Centers for Medicare and Medicaid Services. Hospital conditions of participation for patients' rights. 42CFR 482.13. Baltimore, MD: 1999 (Available at http://cms.hhs.gov/cop/2b.asp).
15. Joint Commission on Accreditation of Healthcare Organizations. Comprehensive accreditation manual for hospitals (CMAH) (http://www.jcaho.org).
16. Dawes SS, Bloniarz PA, Mumpower JL, et al. Supporting psychiatric assessments in emergency rooms. Albany, NY: Center for Technology in Government; 1995.
17. Allen MH, Currier GW, Hughes DH, et al. The expert consensus guideline series: Treatment of behavioral emergencies. Postgrad Med Special Report May 2001:1-88.
18. Djulbegovic B, Hadley T. Evaluating the quality of clinical guidelines: Linking decisions to medical evidence. Oncology 1998;12(11A):310-4.
19. Shekelle PG, Kahan JP, Bernstein SJ, et al. The reproducibility of a method to identify the overuse and underuse of medical procedures. N Engl J Med 1998;338:1888-95.
20. McEvoy JP, Weiden PJ, Smith TE, et al. The expert consensus guideline series: Treatment of schizophrenia. J Clin Psychiatry 1996;57(suppl 12b):1-58.
21. March JS, Frances A, Carpenter D, et al. The expert consensus guideline series: Treatment of obsessive-compulsive disorder. J Clin Psychiatry 1997;58(suppl 4):1-72.
22. Alexopoulos GS, Silver JM, Kahn DA, et al. The expert consensus guideline series: Treatment of agitation in older persons with dementia. Postgrad Med Special Report 1998; April:1-88.
23. McEvoy JP, Scheifler PL, Frances A. The expert consensus guideline series: Treatment of schizophrenia 1999. J Clin Psychiatry 1999;60(suppl 11):1-80.
24. Foa EB, Davidson JRT, Frances A. The expert consensus guideline series: Treatment of posttraumatic stress disorder. J Clin Psychiatry 1999;60(suppl 16):1-76.
25. Sachs GS, Printz DJ, Kahn DA, et al. The expert consensus guideline series: Medication treatment of bipolar disorder 2000. Postgrad Med Special Report 2000;April:1-104.
26. Rush AJ, Frances A. Expert consensus guideline series: Treatment of psychiatric and behavioral problems in mental retardation. AJMR 2000;105:159-228.
27. Altshuler LL, Cohen LS, Moline ML, et al, eds. The expert consensus guideline series: Treatment of depression in women 2001. Postgrad Med Special Report 2001;March:1-116.
28. Alexopoulos GS, Katz IR, Reynolds CF. The expert consensus guideline series: Pharmacotherapy of depressive disorders in older patients. Postgrad Med Special Report 2001;October: 1-86.
29. Kahn DA, Docherty JP, Carpenter D, et al. Consensus methods in practice guideline development: A review and description of a new method. Psychopharmacol Bull 1997;33: 631-9.
30. Brook RH, Chassin MR, Fink A, et al. A method for the detailed assessment of the appropriateness of medical technologies. Int J Tech Assess Health Care 1986;2:53-63.
31. Jacoby HI, Brodie DA. Laparoscopic herniorrhaphy: Diagnostic and therapeutic technology assessment. JAMA 1996;275:1075-82.
32. Allen MH, ed. Acute care of the agitated psychotic patient. J Clin Psychiatry 2000;61(suppl 14):1-55.
33. Centers for Medicare and Medicaid Services. Hospital CoP for Patients' Rights: Questions and Answers. US Dept of Health and Human Services. Baltimore, MD: October 10, 2001. (Available at http://cms.hhs.gov/cop/2b1.asp).
34. Sheline Y, Nelson T. Patient choice: Deciding between psychotropic medication and physical restraints in an emergency. Bull Am Acad Psychiatry Law 1993;21:321-9.
35. Anderson WH, Kuehnle JC, Catanzano DM. Rapid treatment of acute psychosis. Am J Psychiatry 1976;133:1076-8.
36. Neborsky R, Janowsky D, Munson E, et al. Rapid treatment of acute psychotic symptoms with high- and low-dose haloperidol. Arch Gen Psychiatry 1981;38:195-9.
37. Stotsky BA. Relative efficacy of parenteral haloperidol and thiothixene for the emergency treatment of acutely excited and agitated patients. Dis Nerv Syst 1977;38:967-73.
38. Binder R, Glick I, Rice M. A comparative study of parenteral molindone and haloperidol in the acutely psychotic patient. J Clin Psychiatry 1981;42:203-6.
39. Paprocki J, Versiani M. A double-blind comparison between loxapine and haloperidol by parenteral route in acute schizophrenia. Curr Ther Res Clin Exp 1977;21:80-100.
40. Tuason VB. A comparison of parenteral loxapine and haloperidol in hostile and aggressive acutely schizophrenic patients. J Clin Psychiatry 1986;47:126-9.
41. Reschke RW. Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia. Dis Nerv Sys 1974;35:112-5.
42. Gerstenzang ML, Krulisky TV. Parenteral haloperidol in psychiatric emergencies: Double-blind comparison with chlorpromazine. Dis Nerv Syst 1977;38:581-3.
43. Chambers RA., Druss BG. Droperidol: Efficacy and side effects in psychiatric emergencies. J Clin Psychiatry 1999;60:664-7.
44. van Leeuwen AMH, Molders J, Sterkmans P, et al. Droperidol in acutely agitated patients: A double-blind placebo-controlled study. J Nerv Ment Dis 1977;164:280-3.
45. Resnick M, Burton BT. Droperidol vs haloperidol in the initial management of acutely agitated patients. J Clin Psychiatry 1984;45:298-9.
46. Thomas H, Schwartz E, Petrilli R. Droperidol versus haloperidol for chemical restraint of agitated and combative patients. Ann Emerg Med 1992;21:407-13.
47. Richards JR, Derlet RW, Duncan DR. Chemical restraint for the agitated patient in the emergency department: Lorazepam versus droperidol. J Emerg Med 1998;16:567-73.
48. Buckley P, Bartell J, Donenwirth K, et al. Violence and schizophrenia; Clozapine as a specific antiaggressive agent. Bull Am Acad Psychiatry Law 1995;23:607-11.
49. Glazer WM, Dickson RA. Clozapine reduces violence and persistent aggression in schizophrenia. J Clin Psychiatry 1998;59(suppl 3):8-14.
50. Czobor P, Volavka J, Meibach RC. Effect of risperidone on hostility in schizophrenia. J Clin Psychopharmacol 1995;15: 243-9.
51. Chengappa KNR, Levine J, Ultich R, et al. Impact of risperidone on seclusion and restraint in a state psychiatric hospital. Presented at the 40th annual meeting of the New Clinical Drug Evaluation Unit, Boca Raton, FL, May 30-June 2, 2000.
52. Buckley PF, Ibrahim ZY, Singer B, et al. Violence and schizophrenia: Efficacy of risperidone. J Am Acad Psychiatry Law 1997;25:173-81.
53. Beasley CM, Saylor ME, Kiesler GM, et al. The influence of pharmacotherapy on self-directed and externally directed aggression in schizophrenia (abstract). Schizophr Res 1998;29:28.
54. Goldstein JM. "Seroquel" (quetiapine fumarate) reduces hostility and aggression in patients with acute schizophrenia. Presented at the 151st annual meeting of the American Psychiatric Association, Toronto, Ontario, Canada, May 30-June 5, 1998.
55. Hellewell JSE, Cameron-Hands D, Cantillon M. Seroquel: Evidence for efficacy in the treatment of hostility and aggression. Schizophr Res 1998;29:154-5.
56. Lucey JV, Brook S, Daniel DG, et al. Intramuscular (IM) ziprasidone: A novel treatment for the short-term management of agitated psychotic patients. Presented at the 10th Biennial Winter Workshop on Schizophrenia; Davos, Switzerland, Feb 5-11, 2000.
57. Currier GW, Simpson GM. Risperidone liquid concentrate plus lorazepam versus intramuscular haloperidol plus lorazepam for treatment of psychotic agitation. J Clin Psychiatry 2001;62: 153-7.
58. Jones B, Taylor CC, Meehan K. The efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms. J Clin Psychiatry 2001;62(suppl 2):22-4.
59. Lesem MD, Zajecka JM, Swift RH, et al. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry 2001;62:12-8.
60. Brook S, Lucey JV, Gunn KP. Intramuscular ziprasidone compared with intramuscular haloperidol for the treatment of acute psychosis. J Clin Psychiatry 2000;61:933-41.
61. Battaglia J, Moss S, Rush J, et al. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med 1997;15:335-40.
62. Bienek SA, Ownby RL, Penalver A, et al. A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation. Pharmacotherapy 1998;18:57-62.
63. Salzman C, Solomon D, Miyawaki E, et al. Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. J Clin Psychiatry 1991;52:177-80.
64. Foster S, Kessel J, Berman ME, et al. Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. Int Clin Psychopharmacol 1997;12: 175-9.
65. Salzman C, Green A, Rodriguez-Villa F, et al. Benzodiazepines combined with neuroleptics for management of severe disruptive behavior. Psychosomatics 1986;27(suppl 1):17-22.
66. Wyant M, Diamond B, O'Neal E, et al. The use of midazolam in acutely agitated psychiatric patients. Psychopharmacol Bull 1990;26:126-9.
67. Chouinard G, Annable L, Turnier L, et al. A double-blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and I.M. haloperidol in agitated psychotic patients with manic symptoms. Can J Psychiatry 1993;38(suppl 4):S114-21.
68. Dorevitch A, Katz N, Zemishlany Z, et al. Intramuscular flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior. Am J Psychiatry 1999;156:142-4.
69. Binder RL, McNiel DE. Emergency psychiatry: Contemporary practices in managing acutely violent patients in 20 psychiatric emergency rooms. Psychiatr Serv 1999;50:1553-4.
70. American Hospital Formulary Service Drug Information 28:24:08. Bethesda, MD: American Society of Health System Pharmacists, 1998.
71. Medicines Control Agency. Important safety message: Discontinuation of Droleptan tablets, suspension and injection (droperidol). (Available from http://www.mca.gov.uk/ourwork/monitorsafequalmed/safetymessages/ droleptan.html)
72. Food and Drug Administration. Available at http://www.fda.gov/bbs/topics/ANSWERS/2001/ANS01123.html
73. Currier GW. Atypical antipsychotic medications in the psychiatric emergency service. J Clin Psychiatry 2000;61(suppl 14):21-6.
74. Baldessarini RJ, Cohen BM, Teicher M. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 1988;45:79-91.
75. Breitbart W, Marotta R, Platt MM, et al. A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry 1996;153:231-7.
76. van Harten PN, van Trier JCAM, Horwitz EH, et al. Cocaine as a risk factor for neuroleptic-induced acute dystonia. J Clin Psychiatry 1998;59:128-30.
77. American Psychiatric Association. Practice guideline for the treatment of patients with substance use disorders: Alcohol, cocaine, opioids. Am J Psychiatry 1995;152(suppl 11):1-59.
78. Ghaemi SN. New treatments for bipolar disorder: The role of atypical neuroleptic agents. J Clin Psychiatry 2000;61(suppl 14):33-42.
79. Hirschfeld RM, Allen MH, McEvoy JP, et al. Safety and tolerability of oral loading divalproex sodium in acutely manic bipolar patients. J Clin Psychiatry 1999;60:815-8.
80. Altshuler LL, Cohen L, Szuba MP, et al. Pharmacologic management of psychiatric illness during pregnancy: Dilemmas and guidelines. Am J Psychiatry 1996;153:592-606.
81. Physicians' Desk Reference. Montvale, NJ: Thomson PDR; 2003: 3551.
82. Salzman C. Use of benzodiazepines to control disruptive behavior in inpatients. J Clin Psychiatry 1988;49(suppl):13-5